Mandate Vinge advises Isofol in connection with IPO

March 14, 2017

Vinge has advised Isofol Medical AB (publ) in connection with its listing on Nasdaq First North Premier. As a part of the offer, a new issue of shares directed to the general public and institutional investors has been conducted which is expected to generate MSEK 430-473 for Isofol depending on whether an over-subscription option is exercised.

The prospectus is expected to be published on 20 March 2017 and the first day of trading on First North Premier is planned for 4 April 2017. The subscription price in the offer is SEK 29 per share, which corresponds to a value of Isofol of approximately MSEK 487 prior to the offer.

Isofol is an oncology company which clinically develops Modufolin which is a first choice medicament in conjunction with treatment of spread colorectal cancer and is standard therapy in conjunction with high dosage treatment with metotrexat of osteosarcoma. Isofol thus intends to replace the existing folate-based medicaments leukovorin and levoleukovorin, which are currently considered to be the standard treatment within these treatment areas.

Through a worldwide, exclusive license agreement Isofol Medical holds all rights to a global commercialization of Modufolin for cancer treatment as well as access to Merck KGaA’s (Darmstadt, Germany) patent-protected manufacturing process and production capacity.

Vinge’s team primarily consisted of responsible partner Anders Strid, partners Jesper Schönbeck and Magnus Pauli, associates Frida Bäckegren, Natalie Bäck, Petronella Hallberg, Victor Ericsson and company assistant Camilla Andersson.

Clarification of the interpretation of ”nearest suitable railway station”

Road transport performed by Samskip Sia in Sweden has been confirmed to be within the framework of a permitted combined transport through a decision of the Administrative court of Falun in Sweden. The central question in the case was how to interpret the term “nearest suitable railway station”
June 30, 2020

DAC 6 – EU Directive concerning reportable cross‑border tax arrangements

DAC 6 is a EU Directive which entails that advisers are subject to a duty to notify the relevant tax authorities concerning their client’s cross‑border arrangements. The purpose of the information disclosure obligation is to combat tax evasion, tax fraud and tax avoidance.
June 04, 2020

The importance of continuous focus on compliance procedures in disrupting times

A large number of corporations will most certainly be severely impacted by the effects of the Covid-19 pandemic. The new challenges will impact companies’ compliance risks, which are likely to be different and, to a certain extent, increased. It is crucial that - also in disrupting times - internal compliance procedures are maintained and that new risks are identified and mitigated.
May 28, 2020